^
    Back
    Association details:
    Biomarker:EGFR mutation + NOTCH1 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Mol Oncol
    Title:

    NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study

    Published date:
    10/21/2023
    Excerpt:
    The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)....In patients with NOTCH1 co-mutations, gefitinib group had a shorter OS than cis/vin group (Hazard ratio 5.49, 95% CI 1.07-28.00), with a significant interaction (P for interaction=0.039).
    DOI:
    10.1002/1878-0261.13542
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    ASCO 2023
    Title:

    Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.

    Published date:
    05/25/2023
    Excerpt:
    This IMPACT-TR study is an exploratory biomarker study for completely resected, EGFR-mutated NSCLC patients who received gefitinib or cisplatin plus vinorelbine (cis/vin) in a phase III IMPACT study (Trial registration number: UMIN000044738....In the gefitinib group, patients with NOTCH1 mutation had significantly shorter OS (hazard ratio [HR] 4.18, 95%CI 1.65-10.61, p=0.003)…
    DOI:
    10.1200/JCO.2023.41.16_suppl.8524